Compounds and their use as BACE inhibitors

US10053453B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Roland Burli · Pasadena, US
• Mark E. Duggan · Wellesley, US
• Jörg Holenz · Munkfors, SE
• Patrik Johansson · Handen, SE
• Karin Kolmodin · Grafton, GB
• Philip Thorne · Loughborough, GB
• Michael McKenzie · Loughborough, GB

Key dates

• Filing date: Oct 7, 2015
• Grant date: Aug 21, 2018
• Expiry date: Oct 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.